化疗对乙肝病毒携带的癌症患者肝功能的影响  

Effect of Chemotherapy on the Liver Function of HBV Carrier Cancer Patient

作　　者：陈平湖[1] 李剑[1] 刘培光[1] 

机构地区：[1]广东省湛江中心人民医院,湛江524037

出　　处：《热带医学杂志》2006年第9期1037-1039,共3页Journal of Tropical Medicine

摘　　要：目的研究HBV携带的癌症患者化疗对肝功能的影响。方法收集2000年1月～2005年12月的癌症病例136例,其中HBV携带者49例(Ⅰ组),阴性对照87例(Ⅱ组)。检测化疗前后肝功能的变化。结果在Ⅰ组中,治疗前27%(13/49)患者存在AST、ALT异常,化疗后94%(46/49)的患者出现肝功能异常,主要表现为转氨酶的水平上升。在Ⅱ组,治疗前3%(3/87)患者AST和ALT异常,而化疗后仅10%的患者出现肝功能异常。而且,在治疗的近期疗效(CR+PR)上,Ⅱ组优于Ⅰ组(χ2=4.5,P<0.05)。Ⅰ组中,患者中位生存时间46个月(95%CI36～67月),Ⅱ组中位生存时间57个月(95%CI48～71月),LogRank=5.8,P=0.02。结论乙肝病毒携带是癌症患者化疗肝功能受损的危险因素,明显降低患者的近期疗效和远期生存时间。Objective To study the effect of chemiotherapy on liver function of cancer patient who is also a HBV cartier. Methods 136 cancer cases, which were hospitalized in our hospital from 2000 to 2005 were collected, in which 49 cases were HBV infected （group Ⅰ）, 87 cases were HBV negative （group Ⅱ）. The liver function was monitored during chemiotherapy. Results In group Ⅰ, 27% （13/49） of the patient showed abnormal levels of AST and ALT before chemotherapy. After chemiotherapy, 94% （46/49） of the patient in group I showed abnormal liver function, mainly with a increased level of transaminase. In group Ⅱ , 3% （3/87） of the patient showed abnormal levels of AST and ALT before chemotherapy. Only 10% of these patients showed abnormal liver function after chemotherapy. Furthermore, the curative effect of group Ⅱ was better than that of group Ⅰ（CR＋PR）, χ^2=4.5, P〈0.05. In group Ⅰ, the average survival time was 46 months（95% ,CI 36-67 months）, while in group Ⅱ , the average survival time was 57 months （95%, CI 48-71 months）, Log Rank=5.8,P=0.02. Conclusion Hepatitis B virus can cause stronger adverse effect on the lever function in chemotherapy of the cancer patients.

关 键 词：乙肝病毒 癌症 化疗 

分 类 号：R562.62[医药卫生—呼吸系统]